Commercialization of Embryonic Kidney Cell Lines

胚胎肾细胞系的商业化

• 批准号: 7219068
• 负责人: JEFFREY L BARNES
• 金额: $ 14.88万
• 依托单位: PROBETEX, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7219068
• 关键词: Address; Adult; American; Antibodies; Arts; Biomedical Engineering; Cell Line; Cell Separation; Cells; Cellular biology; Characteristics; Cleaved cell; Cloning; Coculture Techniques; Collaborations; Condition; Conditioned Culture Media; Development; Diabetes Mellitus; Differentiation and Growth; Disruption; Dissection; Edetic Acid; Embryo; Funding; Genetic; Goals; Growth; Health Sciences; Human Resources; Immunohistochemistry; In Vitro; Institutes; Kidney; Kidney Diseases; Licensing; Magnetism; Maintenance; Mediating; Mesenchymal; Mesenchyme; Metanephric Diverticulum; Modeling; Mus; Nephrology; Nephrons; Phase; Phenotype; Polymerase Chain Reaction; Preparation; Primordium; Production; Proteomics; Protocols documentation; Publishing; Quality Control; Range; Rattus; Recommendation; Recording of previous events; Renal Tissue; Reporting; Research; Research Personnel; Research Priority; Resources; Reverse Transcriptase Polymerase Chain Reaction; SCID Mice; Sampling; Signal Transduction; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Societies; Stem cells; Strategic Planning; Structure; Surface; System; Techniques; Testing; Texas; Tissues; Universities; Work; base; blastomere structure; cell bank; cell preparation; cell type; commercialization; design; embryonic stem cell; established cell line; human disease; implantation; in vivo; insight; kidney cell; mesangial cell; nephrogenesis; progenitor; programs; repository; research study; stem; subcutaneous; symposium

DESCRIPTION (provided by applicant): There is a crucial need for increases in resources and manpower in research in kidney disease. Probetex was founded as a "Renal Research Resource Company" to create a repository of "off the-shelf" tissue products to provide readily available samples and help investigators to quickly and efficiently explore their ideas on established and standardized models or identified cases of human disease. Part of this goal is to create a repository of kidney cell lines to supplement its portfolio of renal tissue products. Indeed, the isolation, cloning, maintenance, and characterization of renal progenitor cells is identified as a research priority in a Report of the Strategic Planning Conferences sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases and the Council of American Kidney Societies. Included in these priorities are initiatives to 1) develop new organotypic in vitro culture models and 2) develop conditions to permit commitment of stem cells into renal progenitors, and then the maintenance of these differentiated cell lines. The basis of this Phase I application (in collaboration with the University of Texas Health Science Center at San Antonio) is to address the above priorities by defining growth and differentiation conditions for three existing kidney progenitor cell lines derived from mouse and rat embryonic primordia and to isolate and characterize new cell lines from developing embryonic kidney. Specific aims are: Aim 1. To characterize the differentiation potential of embryonic metanephric mesenchymal (MM) and ureteric bud (UB) cell lines derived from kidney primordia. Differentiation conditions include growth in co-culture, in specialized conditioned media, and after implantation of the cells individually and in combination in SCID mice. Expression analysis will be conducted using immunohistochemistry and RT-PCR to validate expanded set of expression markers for specific cell types and differentiation states of the cells. Aim 2. To isolate and characterize new embryonic cell lines derived from the nephrogenic zone of embryonic metanephric kidney and characterize the cells using criteria as outlined above; Aims 3 and 4 are designed to establish an Embryonic Kidney Cell Bank and Commercialization Plan for expansion of new cell lines, large-scale production protocols for kidney cell propagation, out-sourcing, and licensing with the intent to expand the scope of cell lines in the Probetex's repository that are available to the company's investigator/ customers.

描述(由申请者提供)：在肾脏疾病的研究方面，迫切需要增加资源和人力。Probetex成立时是一家“肾脏研究资源公司”，目的是创建一个“现成”组织产品储存库，以提供现成的样本，并帮助研究人员快速有效地探索他们对已建立的标准化模型或已确定的人类疾病病例的想法。这一目标的一部分是创建一个肾脏细胞系的储存库，以补充其肾组织产品组合。事实上，在由国家糖尿病和消化及肾脏疾病研究所和美国肾脏学会理事会主办的战略规划会议的一份报告中，肾前体细胞的分离、克隆、维持和鉴定被确定为研究重点。这些优先事项包括：1)开发新的器官型体外培养模型，2)开发条件，允许干细胞向肾前体细胞承诺，然后维持这些分化的细胞系。这一阶段应用的基础(与圣安东尼奥的德克萨斯大学健康科学中心合作)是通过定义来自小鼠和大鼠胚胎原基的三个现有肾脏前体细胞系的生长和分化条件来解决上述优先事项，并从发育中的胚胎肾脏分离和鉴定新的细胞系。目的：1.研究胚胎后肾间充质(MM)和输尿管芽(UB)细胞系的分化潜能。分化条件包括在共培养、特殊条件培养液中以及在SCID小鼠中单独和联合植入细胞后的生长。将使用免疫组织化学和RT-PCR进行表达分析，以验证针对特定细胞类型和细胞分化状态的扩展表达标记集。目的2.从胚胎后肾的肾区分离和鉴定新的胚胎细胞系，并使用上述标准对细胞进行鉴定；AIMS 3和4旨在建立胚胎肾脏细胞库和商业化计划，以扩展新细胞系、肾脏细胞繁殖、外包和许可的大规模生产方案，目的是扩大Probetex储存库中可供公司研究人员/客户使用的细胞系的范围。